The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms
Open accessAbstract
Purpose: mTOR and P70 S6 kinase (S6K) play a key role in regulating protein translation. The role of mTOR and S6K in hepatocellular carcinoma has not been investigated, but this pathway is of particular interest because an effective inhibitor, rapamycin, is available. This study was undertaken to determine the prevalence and clinicopathological correlates of mTOR pathway activation in hepatocellular carcinoma and to determine whether rapamycin inhibits the pathway in cell culture. Experimental Design: Total and phosphorylated mTOR and S6K protein expression were studied by immunohistochemistry in hepatocellular carcinomas (n = 73), fibrolamellar carcinomas (n = 13), and hepatic adenomas (n = 15). Results were correlated with tumor growth pattern as defined by the WHO (trabecular, pseudoglandular/acinar, compact, and scirrhous), tumor size, Ki-67 proliferation index, and the modified Edmondson nuclear grade, which has a scale of 1 to 4. HepG2 and Hep3B cell lines were treated with rapamycin to see the effect on proliferation and S6K phosphorylation. Results: Increased expression of total mTOR was seen in 5% of hepatocellular carcinoma, whereas overexpression of phospho-mTOR was evident in 15% of hepatocellular carcinoma. Phospho-mTOR positivity correlated with increased expression of total S6K, which was found in 45% of cases. Total S6K overexpression was positively correlated with tumor nuclear grade, inversely with tumor size, and was unassociated with the proliferation index or WHO growth pattern. Rapamycin treatment of HepG2 and Hep3B cell lines markedly inhibited cell proliferation and reduced S6K phosphorylation in both cell lines. Conclusions: The mTOR pathway is activated in a subset of hepatocellular carcinoma. Rapamycin can inhibit proliferation of neoplastic hepatocytes in cell culture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1
Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., & Sabatini, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1432 · Cited by 1,138
NAVÉ, B. T., Ouwens, D. M., Withers, D. J., Alessi, D. R., & Shepherd, P. R. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3440427 · Cited by 932
Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family.
Jefferies, H. B., Reinhard, C., Kozma, S. C., & Thomas, G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4441 · Cited by 623
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
Grunwald, V., & Hidalgo, M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.851 · Cited by 383
Regulation of the p70 S6 Kinase by Phosphorylation in Vivo
Weng, Q.-P., Kozlowski, M., Belham, C., Zhang, A., Comb, M. J., & Avruch, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16621 · Cited by 375
Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma
MONTALTO, G., CERVELLO, M., GIANNITRAPANI, L., DANTONA, F., TERRANOVA, A., & CASTAGNETTA, L. A. M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04090.x · Cited by 312
Kim, J. E., & Chen, J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.011511898 · Cited by 200
Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors
Xu, G. H., Zhang, W., Bertram, P. G., et al. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.4.893 · Cited by 142
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“It is activated in 40–50% of HCCs [312,313].”
BackgroundInfluentialForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
Metadata
- Authors
- Sahin, F., Kannangai, R., Adegbola, O., Wang, J., Su, G., & Torbenson, M.
- Venue
- Clinical Cancer Research
- Published
- 2004-12-15
- Volume
- 10
- Issue
- 24
- Pages
- 8421-8425
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2155514044
- Cited by
- 382
- References
- 12
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-0941
- The paper
- Sahin, F., Kannangai, R., Adegbola, O., Wang, J., Su, G., & Torbenson, M. (2004). mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-0941
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.